For patients who have had a cryptogenic stroke and have a patent foramen ovale (PFO), clinical trials have shown that they can benefit from PFO closure.2-4
The Amplatzer PFO occluder significantly lowers the risk of recurrent ischemic stroke, and furthermore it offers an excellent safety profile.1
PFO Trials Represent a Turning Point
Three large clinical trials have confirmed the superiority of PFO closure to medical management in reducing risk of stroke recurrence.2-4
One study, the RESPECT trial,2 is notable for several reasons:
- Excellent safety and efficacy outcomes from the largest PFO trial to date
- More patients enrolled and evaluated
- The most extensive patient follow-up: 5,810 patient years of data
First on the Market, Still First Worldwide
The Amplatzer PFO Occluder set the standard, pioneering treatment with a device developed specifically for PFO closure. Such leadership is one reason physicians can rely on Amplatzer since:
- As an industry-leading design, it facilitates easy closure
- Over 100,000 devices have been implanted worldwide1
Hear from RESPECT Trial Principal Investigator
Jeffrey Saver, MD, discusses the data supporting the benefits of PFO closure.
Implant Animation
PFO closure with the Amplatzer occluder is demonstrated in this brief video.
AP2947037-WBO Rev. A
- Data on file at Abbott.
- Saver JL, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017; 377:1022-1032. doi: 10.1056/NEJMoa1610057.
- Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017; 377: 1033-1042. doi: 10.1056/NEJMoa1707404.
- Mas J-L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011-1021 and supplementary appendix. doi: 10.1056/NEJMoa1705915.